Claravant has launched the first external rating system designed to assess and rate drug development. Analogous to Standard & Poor’s or Moody’s financial investment analysis, this system would examine drug development and assess how likely a given drug candidate is to succeed.  Using a team of experts, many of them former FDA directors, with experience in all phases of drug development and regulatory review, Claravant analyzes each drug development project based on  175 differen...